Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance
Cheol Soo Choi(Gachon University), Gerald I. Shulman(Howard Hughes Medical Institute), David B. Savage(Google (United States)), Amy Wang(Yale University), Sanjay Bhanot(Ionis Pharmaceuticals (United States)), Xian‐Man Zhang(Yale University), Zhenxiang Liu(Yale University), Varman T. Samuel(VA Connecticut Research and Education Foundation), Sheene Kim(Yale University), Brett P. Monia(Ionis Pharmaceuticals (United States)), Susanne Neschen(Yale University), Alberto Distefano(Yale University), Ameya Kulkarni(Yale University), Katsutaro Morino(Kagoshima University), Xing Yu(Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine), John G. Geisler(Ionis Pharmaceuticals (United States)), Dongyan Zhang(Yale University), Mario Kahn(Yale University), Sanjay K. Pandey(Ionis Pharmaceuticals (United States)), Gary W. Cline(Yale University)
Cited by 375
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity
|Journal of Clinical Investigation|1999|1.3k